Beliefs about medicines' association with endocrine therapy adherence in early breast cancer survivors in Croatia.
Ana Dugonjić OkrošaTajana SilovskiNatalija Dedić PlavetićHrvoje SilovskiAna KovačićIva MucaloPublished in: Acta pharmaceutica (Zagreb, Croatia) (2023)
This observational, cross-sectional study conducted at the University Hospital Centre Zagreb (UHC Zagreb) aimed to explore patients' beliefs about adjuvant endocrine therapy (AET) as well as their association with non-adherence and sociodemographic and clinical factors. Out of 420 early breast cancer (BC) patients included in the study, 79.5 % perceived AET necessary and important for their health, as measured by the Belief About Medicines Questionnaire (BMQ), with the mean necessity score (20.4 ± 3.68) significantly higher than the mean concerns score (13 ± 4.81) ( p < 0.001). Based on the Medication Adherence Report Scale (MARS-5), 44.4 % ( n = 182) of the participants were non-adherers, out of which 63.2 % ( n = 115) were unintentional and 36.8 % ( n = 67) intentional non-adherers. Significantly higher concern beliefs were found among patients that were younger ( p < 0.001), employed ( p < 0.001), intentionally non-adherent to AET ( p = 0.006), had a lower body-mass index ( p = 0.005) and a higher level of education ( p < 0.001), were premenopausal at the time of diagnosis ( p < 0.001), taking tamoxifen treatment ( p = 0.05) and receiving ovarian suppression ( p < 0.001). Younger patients should be recognized as being at risk of non-adherence as they hold greater concern beliefs about medicines.
Keyphrases
- end stage renal disease
- ejection fraction
- body mass index
- newly diagnosed
- chronic kidney disease
- healthcare
- peritoneal dialysis
- physical activity
- early stage
- prognostic factors
- stem cells
- adipose tissue
- cross sectional
- type diabetes
- patient reported outcomes
- metabolic syndrome
- bone marrow
- patient reported
- early breast cancer
- insulin resistance
- social support